share_log

Exicure | 8-K: Current report

Exicure | 8-K: Current report

Exicure | 8-K：重大事件
美股sec公告 ·  06/25 16:26
Moomoo AI 已提取核心訊息
Exicure, Inc., a biotechnology company listed on The Nasdaq Stock Market, received a notification of non-compliance from Nasdaq on June 20, 2024. The notice indicated that Exicure did not meet the minimum stockholders' equity requirement of $2,500,000 as stipulated by Nasdaq Listing Rule 5550(b)(1), which is essential for the continued listing of its common stock. In response to this deficiency, Exicure has announced its intention to address the issue during its pending appeal to the Nasdaq Hearings Panel, which is scheduled for July 9, 2024. The company is actively working to resolve the compliance issue and regain its standing with Nasdaq's listing requirements.
Exicure, Inc., a biotechnology company listed on The Nasdaq Stock Market, received a notification of non-compliance from Nasdaq on June 20, 2024. The notice indicated that Exicure did not meet the minimum stockholders' equity requirement of $2,500,000 as stipulated by Nasdaq Listing Rule 5550(b)(1), which is essential for the continued listing of its common stock. In response to this deficiency, Exicure has announced its intention to address the issue during its pending appeal to the Nasdaq Hearings Panel, which is scheduled for July 9, 2024. The company is actively working to resolve the compliance issue and regain its standing with Nasdaq's listing requirements.
生物技術公司Exicure，Inc.在納斯達克股票市場上市，於2024年6月20日收到納斯達克的不符合通知。該通知指出，Exicure未滿足納斯達克規定的5550(b)(1)上市規則所要求的最低股東權益要求250萬美元，這對其普通股繼續上市至關重要。作爲對該缺陷的回應，Exicure已宣佈在其待處理的上訴納斯達克聽證小組之際，即2024年7月9日解決這一問題的意圖。該公司正在積極努力解決合規問題，恢復其符合納斯達克的上市要求。
生物技術公司Exicure，Inc.在納斯達克股票市場上市，於2024年6月20日收到納斯達克的不符合通知。該通知指出，Exicure未滿足納斯達克規定的5550(b)(1)上市規則所要求的最低股東權益要求250萬美元，這對其普通股繼續上市至關重要。作爲對該缺陷的回應，Exicure已宣佈在其待處理的上訴納斯達克聽證小組之際，即2024年7月9日解決這一問題的意圖。該公司正在積極努力解決合規問題，恢復其符合納斯達克的上市要求。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息